Story thread · 2 reports / 2 sources
Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter
seekingalpha.com · 17h · first report
The coverage
- Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
markets.businessinsider.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.